Cronos Group Inc. Stock price

Equities

CRON

CA22717L1013

Pharmaceuticals

Market Closed - Toronto Stock Exchange 04:00:00 2023-12-01 pm EST Intraday chart for Cronos Group Inc. 5-day change 1st Jan Change
2.830 CAD +2.54% +2.17% -17.73%
Sales 2023 * 120 M 89.14 M Sales 2024 * 147 M 109 M Capitalization 1,079 M 798 M
Net income 2023 * -49.00 M -36.27 M Net income 2024 * -13.00 M -9.62 M EV / Sales 2023 *
-0,64x
Net cash position 2023 * 1,156 M 856 M Net cash position 2024 * 1,174 M 869 M EV / Sales 2024 *
-0,65x
P/E ratio 2023 *
-21,5x
P/E ratio 2024 *
-61,7x
Employees 447
Yield 2023 *
-
Yield 2024 *
-
Free-Float 52.47%
More Fundamentals * Assessed data
Dynamic Chart
Cronos Group Edges Down Premarket as it Raises C$23 Million in a Sale and Leaseback of an Ontario Property MT
Cronos Group Brief: Entering into agreement for the sale-leaseback of its Stayner, Ontario facility MT
Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. for CAD 23 million. CI
Transcript : Cronos Group Inc., Q3 2023 Earnings Call, Nov 08, 2023 CI
Cronos Group Up 3.7% Premarket as its Q3 Loss Narrows on Sales Gain MT
Cronos Group Brief: Company maintains its expectation that the net change in cash will be positive in 2024 MT
Cronos Group Brief: Anticipates that net change in cash, defined as sum of cash and cash equivalents and short-term investments, will decline by less than US$5-$10 million in the last three months of fiscal year 2023 MT
Cronos Group Brief: Reiterates its previously announced operating expense savings target of US$20-$25 million in 2023, and planned incremental operating expense savings of $10-$15 million in 2024 MT
Cronos Group Brief: Citing "Industry-leading" balance sheet with US$840 million in cash and short-term investment MT
Cronos Group Brief: On a constant currency basis, net revenue in Q3 2023 increased by 27% year-over-year to US$26.0 million MT
Cronos Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cronos Group Brief: Net revenue in Q3 2023 increased by 22% year-over-year to US$24.8 million MT
North American Morning Briefing : Stock Futures -2- DJ
Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis Market CI
Cronos Group Brief: Unveiling its New THCV Products MT
More news
1 day+2.54%
1 week+2.17%
Current month+2.54%
1 month+11.86%
3 months+5.99%
6 months+19.41%
Current year-17.73%
More quotes
1 week
2.58
Extreme 2.58
2.83
1 month
2.51
Extreme 2.51
2.90
Current year
2.15
Extreme 2.145
3.57
1 year
2.15
Extreme 2.145
4.88
3 years
2.15
Extreme 2.145
20.08
5 years
2.15
Extreme 2.145
32.95
10 years
0.14
Extreme 0.14
32.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 36 2015
Director of Finance/CFO 40 Nov. 13
Chief Tech/Sci/R&D Officer 40 -
Members of the board TitleAgeSince
Director/Board Member 47 2021
Director/Board Member 56 2018
Director/Board Member 51 2016
More insiders
Date Price Change Volume
23-12-01 2.830 +2.54% 149,893
23-11-30 2.760 +3.37% 277,382
23-11-29 2.670 +1.14% 65,055
23-11-28 2.640 -0.75% 107,709
23-11-27 2.660 -3.97% 60,081

Delayed Quote Toronto Stock Exchange, December 01, 2023 at 04:00 pm EST

More quotes
Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, Lord Jones, Happy Dance and PEACE+. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd., Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd., and Cronos Israel G.S. Pharmacy Ltd.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
D-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
2.830CAD
Average target price
3.378CAD
Spread / Average Target
+19.35%
Consensus
  1. Stock
  2. Equities
  3. Stock Cronos Group Inc. - Toronto Stock Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer